Surgical Treatment of Gastrointestinal Stromal Tumors (GISTs) by António M. Gouveia & José Manuel Lopes
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Surgical Treatment of Gastrointestinal  
Stromal Tumors (GISTs)  
António M. Gouveia1,3,4 and José Manuel Lopes2,3,4 
1Department of Surgery, Hospital de São João, Porto,  
2Department of Pathology, Hospital de São João, Porto,  




Gastrointestinal stromal tumors (GISTs) are the most common gastrointestinal tract (GI) 
mesenchymal tumors (Mazur and Clark 1983; Howe, Karnell et al. 2001), accounting for ~1-
3% of all malignant neoplasms in this location. Most GISTs are sporadic, but there are 
hereditary forms, including some families with germline KIT and PDGFRA gene mutations. 
GIST diagnosis must be confirmed by immunohistochemistry of tumors, and integrated 
with other clinical and morphological features. GISTs usually express CD117 (95%) and 
CD34 (70%). Biological behavior is uncertain and classification (including largest size, 
mitotic rate and GI site) in risk categories is useful for predicting clinical behavior of GISTs. 
Other parameters have been described as prognostic of GISTs, including RKIP expression 
(Martinho, Gouveia et al. 2009). These tumors are characterized by oncogene mutations in 
KIT (up to ~85%) or PDGFRA (5-8%) receptor tyrosine kinases (RTKs) genes (Heinrich, 
Corless et al. 2003; Corless and Heinrich 2008; Gomes, Gouveia et al. 2008; Hoeben, Schoffski 
et al. 2008; Gajiwala, Wu et al. 2009; Liegl-Atzwanger, Fletcher et al. 2010), and rarely BRAF 
(Agaram, Wong et al. 2008; Agaimy, Terracciano et al. 2009; Martinho, Gouveia et al. 2009; 
Hostein, Faur et al. 2010); 10-15% does not harbor any of the aforementioned gene 
mutations: so called wild-type GISTs. KIT/ PDGFR mutations in GISTs are biodiversity 
markers, tyrosine kinase inhibitor (TKI) targets, predictive markers of TKI response, 
prognostic markers of tumor recurrence/progression, and frequent cause of TKI resistance. 
Thus, good clinical practice in bio-therapeutic decision of GIST patients should include 
mutational analysis status of the tumors. 
Most importantly, complete surgical resection, without lymph node dissection, is considered 
standard treatment for primary localized GISTs (without peritoneal dissemination or 
metastatic disease), and is the only potential curative treatment for patients harboring these 
tumors. 
2. Localized primary disease 
There is a general consensus that the definitive treatment of primary GISTs with dimensions 
≥ 2 cm and without evidence of peritoneal dissemination or distant metastases is complete 
www.intechopen.com
 
Gastrointestinal Stromal Tumor 
 
62
macroscopic surgical resection (Casali and Blay 2010; Demetri, von Mehren et al. 2010). 
However, when esophagogastric or duodenal subepithelial nodules with < 2 cm diameter 
are detected, the standard procedure consists in endoscopic ultrasound (EUS) assessment 
and active surveillance of the individual patient, because many of these small nodules, 
when they correspond to GISTs, are tumors of low biological risk (Fletcher, Berman et al. 
2002; Miettinen and Lasota 2006) or whose clinical behavior remains to be clarified. Surgery 
is reserved for patients whose tumor increases in dimension or is symptomatic. The results 
of a recent retrospective analysis (Lok, Lai et al. 2009)  indicate that only some (3 out of 23; 
13.0%) of the small tumors without high-risk EUS characteristics (large dimension, irregular 
extraluminal limits, heterogeneous echo pattern, presence of cystic areas, and hyperechoic 
foci) progressed during the long-term follow-up with EUS. As an alternative, the decision 
can be shared in an individual base with the patient, either to opt for an initial histological 
evaluation (needle biopsy) or for the tumor excision, when the morbidity is not substantial. 
On the other hand, when facing intra-abdominal nodules without endoscopic evaluation, 
the laparoscopy/laparotomy resection is the standard approach. Also for rectal nodules (or 
in the recto-vaginal space), the best management must be the accomplishment of 
biopsy/resection, after EUS evaluation, regardless of the tumor dimension, because GISTs 
in this location display high biological risk, and the local implications of a surgical 
intervention in this region is more critical, mostly in tumors of great dimensions. 
The guidelines of the ESMO and the NCCN coincide in the recommendation that tumors 
with dimension > 2 cm must be resected (Casali and Blay 2010; Demetri, von Mehren et al. 
2010), because being GISTs, they imply a higher risk of aggressive behavior.  
For patients with localized primary GIST, the surgical resection continues to be the only 
possibility of cure of their illness. In our experience we obtained complete macroscopic 
resection (R0 or R1) in 92.3% of GISTs and microscopic negative margins (R0) in 75% of 
cases. 5-year disease-specific survival (DSS) and recurrence-free survival (RFS) was 87.7% 
and 89.8%, respectively, after surgical resection of patient’s primary GIST. The recurrence 
rate was significantly (p=0.045) lower in R0 cases. In the multivariate analysis, only the 
presence of macroscopic residual tumor (R2) was significantly associated (p=0.013) with 
shorter DSS (Gouveia, Pimenta et al. 2008). The DSS and RFS values in our patients fit with 
results published in other studies (DeMatteo, Lewis et al. 2000; Crosby, Catton et al. 2001; 
Fujimoto, Nakanishi et al. 2003; Langer, Gunawan et al. 2003; Lin, Huang et al. 2003; Wong, 
Young et al. 2003; Bucher, Taylor et al. 2004; Bucher, Egger et al. 2006; Bumming, Ahlman et 
al. 2006). The recurrence rate was significantly lower in R0 cases, but in multivariate analysis 
only R2 resection was significantly associated with shorter survival of patients. According to 
the actual consensus recommendations (Casali and Blay 2010; Demetri, von Mehren et al. 
2010), our results underline the prognostic importance of complete macroscopic surgical 
tumor resection, with the aim of achieving negative microscopic margins, and avoiding 
tumor rupture.  
The surgery of GISTs should allow a complete margin of normal tissue around the primary 
tumor. The revision of most important published series shows that several authors refer to 
complete macroscopic resection (Ng, Pollock et al. 1992; Crosby, Catton et al. 2001; Pierie, 
Choudry et al. 2001; Eisenberg and Judson 2004; Boni, Benevento et al. 2005; Wu, Lee et al. 
2006) of the tumors, whereas others specify R0 resection (Connolly, Gaffney et al. 2003; 
Langer, Gunawan et al. 2003; Wu, Langerman et al. 2003; Aparicio, Boige et al. 2004; 
Heinrich and Corless 2005; Bucher, Egger et al. 2006; Wardelmann, Buttner et al. 2007) as the 
standard procedure for the surgical treatment of GISTs. Some authors sustain that the 
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microscopic status of the surgical margins (positive or negative), in contrast to the results 
obtained with other malignant solid tumors, does not influences the survival of patients, or 
even the recurrence of GISTs (DeMatteo, Lewis et al. 2000; Pierie, Choudry et al. 2001; 
Demetri, Baker et al. 2007). In a study of 200 patients with GIST, DeMatteo et al. (DeMatteo, 
Lewis et al. 2000) report that the microscopic margins do not significantly influence the 
evolution of the tumors and that recurrence occur most probably due to the intrinsic 
characteristics of the tumors. However, in the reported series, the relative small number of 
cases with positive microscopic margins after macroscopically complete resection is an 
important limitation to the clarification of the aforementioned author’s suggestion. 
Additionally, this series included a substantial number of large dimension GISTs with high 
biological risk, in which complete macroscopic resection may not prevent the occurrence of 
recurrence (e.g., metastases) of the tumor or the shorter survival of these patients. In fact, the 
analysis of the results reported by DeMatteo et al. confirms that most resections were 
performed in patients with large GISTs with high biological risk (Lin, Huang et al. 2003; 
Bucher, Egger et al. 2006). The value of negative surgical margin, for instance in GISTs > 10 
cm, is highly controversial, since it is possible to argue that those tumors may release to the 
peritoneal cavity cells not detectable clinically (DeMatteo, Lewis et al. 2000; Crosby, Catton 
et al. 2001). In addition, some of these reported results may be biased by the effect of 
adjuvant treatment performed in advanced or incompletely removed GISTs (He, Wang et al. 
1988; DeMatteo, Lewis et al. 2000).  
Other authors suggest that R0 resections may influence the prognosis of patients (Lehnert 
1998; Pidhorecky, Cheney et al. 2000; Langer, Gunawan et al. 2003; Lin, Huang et al. 2003; 
Wu, Langerman et al. 2003; Yan, Marchettini et al. 2003; Bucher, Egger et al. 2006; Bumming, 
Ahlman et al. 2006; Hinz, Pauser et al. 2006; Ahmed, Welch et al. 2008); however, these 
results can also be influenced by the number of incomplete resections in GISTs of high 
biological risk (Lin, Huang et al. 2003). 
Similar to the reports of DeMatteo et al. e Pierie et al. (Pierie, Choudry et al. 2001), our own 
results reinforce that complete macroscopic resection of GISTs has a positive impact in the 
prognosis, being significantly shorter the specific survival of patients with R2 tumor margin 
status. 
Despite the remaining controversy, R1 margins resection may expose patients to a higher 
risk of tumoral locoregional recurrence of GISTs.  
ESMO and NCCN recommend that in cases with R1 resections one should consider 
widening of resection, whenever the exact location of the lesion is possible to identify and 
the risk of surgical morbidity is low. 
The surgical management recommended for small intestinal GISTs is segmental resection 
with 2-3 cm, and for gastric GISTs 1-2 cm free macroscopically margins (Dematteo, Heinrich 
et al. 2002; Matthews, Walsh et al. 2002; Wardelmann, Buttner et al. 2007; Hohenberger and 
Eisenberg 2010). An intraoperative histological frozen examination of peri-tumoral tissues 
must be compulsory whenever there is a possibility of not avoiding positive tumor surgical 
margins.  
Usually, the resection causes low morbidity in tumors <10 cm, localized to stomach or small 
intestine. In contrast to more common gastrointestinal (GI) carcinomas, GIST does not 
originate from the epithelial layers of GI tract and, therefore, they present different biology 
and behavior implications. These facts are important for the surgical margins status 
procedures and locoregional lymph node management. The surgical procedures can differ, 
depending on the organ where GIST originates, on its precise localization, and the 
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dimensions of the tumor. The treatment goal is complete resection of GIST, with negative 
microscopic margins (R0) and preservation of an intact pseudocapsule (i.e. preventing the 
tumoral rupture) (Casali and Blay 2010; Demetri, von Mehren et al. 2010). 
As GIST does not have generally intraparietal infiltrative features, the attainment of wide 
surgical margins rarely associates with a prognostic benefit for the patients. The present 
recommendations for surgical margins are based on expert experience, consensus meeting 
reports, and application of the pathobiology concepts on GIST (Casali and Blay 2010; 
Demetri, von Mehren et al. 2010). In fact, there is no prospective conclusive evidence that 
allows predicting the relation between the extension of resection margins and the risk of 
local or distant recurrence of GISTs.  
The wedge resection is the most frequent option for GISTs located in the stomach and the 
segmental resection is the procedure of choice for small bowel tumors. For GISTs of large 
dimensions in gastric lesser curvature and/or with pyloric involvement, wedge resection 
may not be possible, and a distal gastrectomy might be a more adequate procedure. Total 
gastrectomy is not usually necessary, but it has to be considered depending on the 
localization (esophagogastric junction) and/or extension of the tumor. 
The rectal GISTs are uncommon and their definitive diagnosis is frequently obtained after 
the anatomopathological study of the surgical specimen. The rectal GIST of small 
dimensions, located in lower third, can be removed with complete parietal resection, 
through a transanal or transsphincteric procedure. However, these type of procedures must 
be performed with due care, because there are lower R0 resections (32% versus 82%) and 
higher rates of local recurrence (77% versus 31%), when compared with the previous lower 
anterior rectal resections, that is the procedure recommended for GISTs of the upper and 
middle thirds of the rectum (Changchien, Wu et al. 2004; Dong, Jun-Hui et al. 2007). 
The surgical technique used to resect GISTs has implications in the occurrence of tumoral 
recurrence. The rupture of the tumor must be strictly prevented in all the GIST cases, 
especially in those which have great cystic or necrotic areas. The enucleation of the GISTs is 
considered an insufficient option, because it can easily not remove part of the pseudo-
capsule, with persistence of viable tumor cells; on the other hand, it also associates with 
more frequent tumoral rupture. For these reasons, the enucleation is not recommended, 
even when the objective is to preserve a vital structure (Nishimura, Nakajima et al. 2007). 
When the GIST develops and presents great dimensions, it can be submitted to a pre-
surgical (neoadjuvant) treatment with imatinib, aiming to get better conditions of 
resectability of a tumor that is, many times, necrotic and friable (Eisenberg, Harris et al. 
2009). This option can facilitate the complete surgical resection associated to tumor response 
to the treatment (Fig. 1), and/or the preservation of the function or the organ, particularly in 
GISTs of the esophagogastric junction, the second portion of the duodenum and the lower 
rectum (Casali and Blay 2010; Demetri, von Mehren et al. 2010). When there is invasion of 
adjacent organs, en bloc resection can be an alternative (Fig. 2). However, it is generally 
accepted that an incomplete resection of the tumor must be only performed as a palliative 
therapeutic option, in cases of hemorrhage, pain or symptoms secondary to the mass effect 
of the tumor.  
When the R0 surgical resection is predicted to result in functional complications or 
important co-morbidities, and the neoadjuvant medical treatment was not efficient or 
cannot be given, the decision to carry a R1 resection must be discussed with the patient. The 
R1 resection can be acceptable in GISTs of low risk. There are no studies that clearly 
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demonstrate the association between R1 surgery and shorter survival of the patients 
(Hohenberger and Eisenberg 2010). 
 
 
Fig. 1. GIST: biopsy microscopic features of an unresectable tumor (A); the tumor was 
submitted to a R0 resection after neoadjuvant imatinib (B). Note the substantial decreasing 
of the tumor cells density (B) with abundant sclero-hyaline stroma and hemorrhagic areas 
(inset) compared to pre-imatinib features (A). 
 
 
Fig. 2. GIST: CT scan of a large dimension GIST invading adjacent transverse colon (A); 
macroscopic aspect of the surgical specimen with R0 resection (B). 
Many authors described that GISTs metastasize rarely for the lymph nodes, even in high 
risk cases. Bucher et al. (Bucher, Egger et al. 2006) described that 5 out of 80 patients (6%) 
with localized GIST developed hematogenous metastases, with or without lymph node 
involvement. In the series of Rutkowski et al. (Rutkowski, Nowecki et al. 2007), that include 
335 patients, only four cases (1.2%) disclosed metastatic lymph nodes. The published studies 
indicate that there is no evidence of benefit for routine lymphadenectomy in the surgical 
treatment of GISTs, except when there is macroscopic lymph node involvement by the 
tumor (DeMatteo, Lewis et al. 2000; van der Zwan and DeMatteo 2005; Bucher, Egger et al. 
2006; Otani, Furukawa et al. 2006; Casali and Blay 2010; Demetri, von Mehren et al. 2010). 
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3. Laparoscopic surgery  
The laparoscopic surgery in GISTs is gradually expanding and being more used in recent 
years. The endoscopic diagnosis improved the capacity to identify gastric GISTs of small 
dimensions that are associated with a low risk of aggressiveness (Fletcher, Berman et al. 
2002; Miettinen and Lasota 2006). The minimally invasive approach has become generally 
used in these tumors, due to the potential benefits of preventing the laparotomy of the 
patients. One should follow the strict oncologic principles of the open surgery: complete 
resection of the tumor with free margins (R0), preventing the dissemination of tumor cells 
into the peritoneal cavity (Otani and Kitajima 2005; Casali and Blay 2010; Demetri, von 
Mehren et al. 2010). In the GISTs of large dimensions, R1 resection can be complicated by 
rupture due to manipulation of the tumor and peritoneal dissemination. Therefore, 
laparoscopic resection has been discouraged in patients with GISTs of great dimensions 
(Blay, Bonvalot et al. 2005; Hohenberger and Eisenberg 2010). However, Novitsky et al. 
(Novitsky, Kercher et al. 2006) suggested that these recommendations should be reviewed, 
because they were not based on evidence but only translated precaution for the 
inexperienced surgeons with this procedure, aiming over all to prevent the increase of the 
incidence of tumor rupture. Several authors proposed the adoption of widened indications 
for the laparoscopic surgery in GISTs (Mochizuki, Kodera et al. 2004; Mochizuki, Kodera et 
al. 2006). Several studies described the accomplishment of laparoscopic resection of tumors 
with dimensions between 0.3 and 12.5 cm (Catena, Di Battista et al. 2008; Hohenberger and 
Eisenberg 2010), supplying evidence for the application of this procedure mainly in gastric 
GISTs. However, there are no controlled randomized studies in prospective clinical trials 
concluded to date to validate these options. 
In the NCCN 2007 update, it is considered acceptable the laparoscopic resection of tumors > 
5 cm, depending on the localization and the morphology, using laparoscopic or hand-
assisted techniques (Novitsky, Kercher et al. 2006; Demetri, Benjamin et al. 2007; Catena, Di 
Battista et al. 2008; Demetri, von Mehren et al. 2010).  
Before initiating the resection of the tumor, a formal throughout exploration of the 
abdominal cavity must be carried out to exclude the eventual presence of peritoneal or liver 
metastases. The use of ultrasound during surgery can be useful in the evaluation of possible 
liver metastases, and in case of suspected lesions, to guide the accomplishment of their 
biopsies. The use of intraoperative flexible endoscopy has been also frequently used to assist 
in more precise localization of small dimension GISTs and in the selection of the most 
adequate technique for the resection in the individual case. To prevent the risk of tumor 
rupture occurrence, GISTs should not be directly manipulated with the laparoscopic 
instruments (Novitsky, Kercher et al. 2006). Although there are no available evidence based 
data, the use of a bag for the removal of the surgical specimen seems to be essential to 
prevent the dissemination of tumor cells into the abdominal cavity or in the orifice of the 
laparoscopic port, and eventually metastases (Novitsky, Kercher et al. 2006; Ronellenfitsch, 
Staiger et al. 2009; Casali and Blay 2010). 
For the treatment of gastric GISTs, different procedures have been used in the diverse 
published series, depending on several factors (e.g., dimension, localization and 
macroscopic features of the tumor): wedge or segmental resections using laparoscopy, 
laparoendoscopy (intragastric) or hand-assisted laparoscopy. The GISTs of the anterior wall 
and of the lesser and greater curvatures of the stomach are generally submitted to wedge 
resection, with linear endoscopic GI anastomosis stapler. The tumors of larger dimensions 
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can be resected with free margins, using the ultrasonic coagulating shears (Novitsky, 
Kercher et al. 2006). The tumors of the posterior wall are many times removed via the lesser 
sac, but the transgastric approach, with anterior gastrotomy, constitutes a valid alternative, 
especially in the GISTs located next to the esophagogastric junction (Matthews, Walsh et al. 
2002; Ludwig, Weiner et al. 2003; Li, Hung et al. 2008; Privette, McCahill et al. 2008). This 
option is, however, technically demanding and there are reports of incomplete resections 
and postoperative complications, such as stenosis and leakage in the suture line. The 
combined intragastric endoscopic-laparoscopic resection has been described as an 
alternative method in the treatment of the esophagogastric junction GISTs (Novitsky, 
Kercher et al. 2006; Ronellenfitsch, Staiger et al. 2009). 
The localization of the tumor does not have to be considered an absolute contraindication 
for minimally invasive surgery, whenever the experience necessary for the technique and all 
the indispensable precautions are considered. However, in GISTs with large dimensions 
and/or with unfavorable localizations, as the gastric lesser curvature or the esophagogastric 
junction, it may not be possible to perform wedge resection with free tumor margins, being 
sometimes necessary to opt for subtotal or total gastrectomy. In these cases, the neoadjuvant 
treatment with imatinib, as suggested in the guidelines of ESMO and NCCN, may be a valid 
option to reduce the dimension of the tumor, and allow a resection with some preservation 
of the organ /function. However, the feasibility and the results of this type of procedures 
need validation from ongoing studies (Eisenberg 2006).  
The laparoscopic surgery can be applied in other anatomic sites, such as rectal GISTs of 
small dimensions. However, the available data relative to the laparoscopic resections of 
GISTs in other (extra gastric) localizations are limited (Demetri, von Mehren et al. 2010). 
The published global results of the laparoscopic surgery describe that the intraoperative and 
postoperative complications are relatively rare, occurring, respectively, in 6.8% and 7.7% of 
the patients (Hohenberger and Eisenberg 2010). The resections elapse with minimum losses 
of blood, satisfying the duration of surgery and short periods of hospital stay (Catena, Di 
Battista et al. 2008; Ronellenfitsch, Staiger et al. 2009). The morbidity related with the 
surgical wound of laparotomy is also prevented. The learning curve in the laparoscopic 
procedures indicates that, with better technical experience, the surgical times will be 
gradually improved (Shin 2005; Avital, Hermon et al. 2006).  
Although the follow-up data of the patients are scarce, not exceeding ~ 5 years of duration 
(Hohenberger and Eisenberg 2010), some series described similar oncologic efficacy in the 
laparoscopic procedures when compared with those obtained with conventional surgery 
(Otani, Ohgami et al. 2000; Novitsky, Kercher et al. 2006; Choi, Kim et al. 2007) 
The applicability of the laparoscopic approach must, therefore, be based in a variety of 
factors, including the characteristics of patient, dimension and the macroscopic morphology 
of the tumor, the pattern of invasion and the localization of the tumor, as well as the 
experience and qualification in laparoscopic surgery of the surgeon (Novitsky, Kercher et al. 
2006). 
The data from the literature indicate that laparoscopic resections or assisted by laparoscopy 
are feasible and associated with reduced rates of recurrence, short periods of internment and 
low morbidity (Otani, Ohgami et al. 2000; Novitsky, Kercher et al. 2006; Otani, Furukawa et 
al. 2006; Nishimura, Nakajima et al. 2007; Huguet, Rush et al. 2008; Nakamori, Iwahashi et 
al. 2008). This procedure must be recommended as the option of choice for the majority of 
patients with the small and intermediate dimension localized gastric GISTs. 
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4. Locally advanced primary GIST 
In the advanced GISTs, without distant metastases, it can be impracticable the 
accomplishment of R0 resection. In these cases, it must be considered the tumoral 
cytoreduction with neoadjuvant imatinib. This option can facilitate the achievement of 
surgical R0 margins and allow a less extensive surgery, with better functional results, as 
suggested by the ESMO and the NCCN recommendations in such circumstances. However, 
these recommendations are based only on publications of retrospective non-randomized 
data (Shah, Sun et al. 2005; Goh, Chow et al. 2006). The primary treatment with imatinib for 
tumor cytoreduction can still be considered in GISTs whenever there is a high risk of 
hemorrhage or tumoral rupture during surgery.  
The maximum therapeutic response is usually reached after 6-12 months of treatment. The 
subsequent surgical intervention can then be safely performed in the majority of the cases 
(Bumming, Andersson et al. 2003; Eisenberg, Harris et al. 2009; Casali and Blay 2010). 
However, it is not always necessary to wait for the maximum response to perform the 
surgery. The mutacional analysis of the tumor can assist to exclude from this therapeutic 
neoadjuvant option GISTs with lower response rates to imatinib (e.g., with PDGFRA D842V 
mutation), and/or allow to change for a more adequate therapeutic option. A PET or 
PET/CT, or the evaluation of the tumor density with CT scan, can be particularly useful in 
the early evaluation of tumor response to the therapeutic option, without delaying the 
surgical intervention in GISTs that do not respond to the treatment (Townsend, Carney et al. 
2004; Goldstein, Tan et al. 2005; Heinicke, Wardelmann et al. 2005; Dimitrakopoulou-
Strauss, Hohenberger et al. 2007). 
It is essential to establish a multidisciplinary therapeutic decision plan (tumor conference) 
involving several specialties, including pathologists, oncologists, radiologists, 
gastroenterologists, and surgeons. The sharing of experiences, available in reference centers 
for sarcomas, including GISTs, and/or in oncologic networks to assist patients, must be 
considered as an essential condition for the adequate individual management of patients 
with GISTs (Casali and Blay 2010). 
5. Conclusion 
Gastrointestinal stromal tumors (GISTs) are the most common gastrointestinal tract (GI) 
mesenchymal tumors. GIST diagnosis must be confirmed by immunohistochemistry, rarely 
by molecular study, and integrated with other clinical and morphological features. 
Biological behavior is uncertain and classification (including largest size, mitotic rate and GI 
site) in risk categories is useful for predicting clinical behavior of GISTs.  
The definitive treatment of primary GISTs ≥ 2 cm without peritoneal dissemination or 
distant metastases is complete macroscopic surgical resection. Some authors sustain that the 
microscopic status (R1 or R0) of the surgical margins does not influences survival, or even 
recurrence of GISTs, while others suggest that R0 resections may influence the prognosis of 
patients. In our experience, the recurrence rate is significantly lower in R0 cases, but in the 
multivariate analysis only R2 is significantly associated with shorter disease specific 
survival of patients with GIST. R1 resection may expose patients to a higher risk of tumor 
locoregional recurrence. The gold standard of ESMO and NCCN recommendations for 
surgery of GIST is complete (R0) resection without tumor rupture.  
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Surgical procedures can change, depending on the involved organ, its precise site, and the 
dimension of GIST. Wedge resection is the most frequent option for GISTs in the stomach, 
and segmental resection for those in the small bowel. For large dimension tumors in the 
gastric lesser curvature and/or with pyloric involvement, a distal gastrectomy may be better 
option, and total gastrectomy may be also considered, depending on the site 
(esophagogastric junction) and/or extension of the GIST. There is no evidence of benefit for 
routine lymphadenectomy in the surgical treatment of GISTs.  
The minimally invasive approach is being commonly used in gastric tumors, avoiding 
laparotomy of patients. Nevertheless, controlled randomized studies in prospective clinical 
trials are warranted to validate this option. Worth mentioning, one should follow in this 
approach the same stringent oncologic standards of open surgery: complete resection (R0) of 
the tumor, avoiding dissemination into the peritoneal cavity. The NCCN 2007 update 
considers suitable the laparoscopic resection of tumors > 5 cm, depending on the site and 
the morphology, using laparoscopic or hand-assisted techniques. Laparoscopic resections or 
assisted by laparoscopy are feasible with reduced rates of recurrence, short periods of 
internment, and low morbidity.  
In locally advanced GISTs, without distant metastases, tumor cytoreduction with 
neoadjuvant imatinib can enable R0 margins and less mutilating surgery, with better 
functional results, as proposed by the retrospective non-randomized based data included in 
ESMO and NCCN recommendations. The mutational analysis of the tumor can assist to 
exclude from the neoadjuvant option GISTs with lower response rates to imatinib (e.g., with 
PDGFRA D842V mutation), and/or allow a more adequate available therapeutic option.  
Considering the persisting controversies, it is essential to set up a multidisciplinary 
therapeutic decision plan involving several specialties. The input of experiences, available in 
reference centers for sarcomas, in addition to the patient involvement and informed consent, 
must be considered as standard of care conditions for the adequate individual management 
of GISTs. 
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